1% for the Planet 标识
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

Claudin-6 (E7U2O) XP® Rabbit mAb #18932

Filter:
  • WB
  • IHC
Western Blotting Image 1: Claudin-6 (E7U2O) XP® Rabbit mAb
Western blot analysis of extracts from OVCAR-3 and DU 145 cells using Claudin-6 (E7U2O) XP® Rabbit mAb (upper) or β-Actin (D6A8) Rabbit mAb #8457 (lower). Negative expression of Claudin-6 in DU 145 cells is consistent with the predicted expression pattern.

To Purchase # 18932

Supporting Data

REACTIVITY H
SENSITIVITY Endogenous
MW (kDa) 23
Source/Isotype Rabbit IgG
Application Key:
  • WB-Western Blotting 
  • IHC-Immunohistochemistry 
Species Cross-Reactivity Key:
  • H-Human 
  • Related Products

Product Information

Product Usage Information

Application Dilution
Western Blotting 1:1000
IHC Leica Bond 1:200 - 1:800
Immunohistochemistry (Paraffin) 1:200 - 1:800

Storage

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

For a carrier free (BSA and azide free) version of this product see product #59648.

Protocol

Specificity / Sensitivity

Claudin-6 (E7U2O) XP® Rabbit mAb recognizes endogenous levels of total Claudin-6 protein. This antibody does not cross-react with Claudin-9 protein.

Species Reactivity:

Human

Source / Purification

Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Val220 of human Claudin-6 protein.

Background

Tight junctions, or zonula occludens, form a continuous barrier to fluids across the epithelium and endothelium. They function in regulation of paracellular permeability and in the maintenance of cell polarity, blocking the movement of transmembrane proteins between the apical and the basolateral cell surfaces. Tight junctions are composed of claudin and occludin proteins, which join the junctions to the cytoskeleton (1,2). The claudin family is composed of 23 integral membrane proteins, and their expression, which varies among tissue types, may determine both the strength and properties of the epithelial barrier. Alteration in claudin protein expression pattern is associated with several types of cancer (2,3). Claudin-1 is expressed primarily in keratinocytes (4) and normal mammary epithelial cells, but is absent or reduced in breast carcinomas and breast cancer cell lines (5,6).

Claudin-6 is a member of the CLDN family that is expressed in epithelial cell sheets. Downregulation of Claudin-6 has been reported in breast invasive ductal carcinoma associated with lymphatic metastasis which may point to a function of Claudin-6 as a tumor suppressor. Claudin-6 is reported to play a role in inhibiting malignancy of breast cancer cells by inducing apoptosis, inhibiting proliferation and migration. Mechanisms of action of Claudin-6 have been described through various signaling pathways such as p38-MAPK, JAKs-STATs, ASK1-JNK, and other pathways (7,8). Regulation of Claudin-6 expression may occur through epigenetic mechanisms (9). Other reports describe aberrant expression in various malignancies (10,11). The clinical significance of Claudin-6 dysregulation has created interest in the potential for pharmaceutical intervention (12-14).
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
SignalStain is a registered trademark of Cell Signaling Technology, Inc.
XP is a registered trademark of Cell Signaling Technology, Inc.
All other trademarks are the property of their respective owners. Visit our Trademark Information page.